• Je něco špatně v tomto záznamu ?

The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients

V. Hlaváč, V. Brynychová, R. Václavíková, M. Ehrlichová, D. Vrána, V. Pecha, M. Trnková, R. Kodet, M. Mrhalová, K. Kubáčková, J. Gatěk, P. Vážan, P. Souček,

. 2014 ; 93 (28) : e255.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15013957

Grantová podpora
NT14055 MZ0 CEP - Centrální evidence projektů

Metabolism of anticancer drugs affects their antitumor effects. This study has investigated the associations of gene expression of enzymes metabolizing anticancer drugs with therapy response and survival of breast carcinoma patients. Gene expression of 13 aldo-keto reductases (AKRs), carbonyl reductase 1, and 10 cytochromes P450 (CYPs) was assessed using quantitative real-time polymerase chain reaction in tumors and paired adjacent nonneoplastic tissues from 68 posttreatment breast carcinoma patients. Eleven candidate genes were then evaluated in an independent series of 50 pretreatment patients. Protein expression of the most significant genes was confirmed by immunoblotting. AKR1A1 was significantly overexpressed and AKR1C1-4, KCNAB1, CYP2C19, CYP3A4, and CYP3A5 downregulated in tumors compared with control nonneoplastic tissues after correction for multiple testing. Significant association of CYP2B6 transcript levels in tumors with expression of hormonal receptors was found in the posttreatment set and replicated in the pretreatment set of patients. Significantly higher intratumoral levels of AKR1C1, AKR1C2, or CYP2W1 were found in responders to neoadjuvant chemotherapy compared with nonresponders. Patients with high AKR7A3 or CYP2B6 levels in the pretreatment set had significantly longer disease-free survival than patients with low levels. Protein products of AKR1C1, AKR1C2, AKR7A3, CYP3A4, and carbonyl reductase (CBR1) were found in tumors and those of AKR1C1, AKR7A3, and CBR1 correlated with their transcript levels. Small interfering RNA-directed knockdown of AKR1C2 or vector-mediated upregulation of CYP3A4 in MDA-MB-231 model cell line had no effect on cell proliferation after paclitaxel treatment in vitro. Prognostic and predictive roles of drug-metabolizing enzymes strikingly differ between posttreatment and pretreatment breast carcinoma patients. Mechanisms of action of AKR1C2, AKR7A3, CYP2B6, CYP3A4, and CBR1 should continue to be further followed in breast carcinoma patients and models.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15013957
003      
CZ-PrNML
005      
20191030131257.0
007      
ta
008      
150420s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MD.0000000000000255 $2 doi
035    __
$a (PubMed)25526449
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hlaváč, Viktor $u From the Toxicogenomics Unit (VH, VB, RV, ME, DV, PS), National Institute of Public Health; 3rd Faculty of Medicine (VH, VB, ME), Charles University, Prague; Department of Oncology (DV), Palacky University Medical School and Teaching Hospital, Olomouc; Institute for the Care for Mother and Child (VP); Biolab Praha, Ltd (MT); Department of Pathology and Molecular Medicine (RK, MM); Department of Oncology (KK), University Hospital Motol, Prague; Department of Surgery (JG), Hospital Atlas; Tomas Bata University (JG); and Department of Pathology (PV), VELAB Ltd, Zlin, Czech Republic. $7 xx0270481
245    14
$a The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients / $c V. Hlaváč, V. Brynychová, R. Václavíková, M. Ehrlichová, D. Vrána, V. Pecha, M. Trnková, R. Kodet, M. Mrhalová, K. Kubáčková, J. Gatěk, P. Vážan, P. Souček,
520    9_
$a Metabolism of anticancer drugs affects their antitumor effects. This study has investigated the associations of gene expression of enzymes metabolizing anticancer drugs with therapy response and survival of breast carcinoma patients. Gene expression of 13 aldo-keto reductases (AKRs), carbonyl reductase 1, and 10 cytochromes P450 (CYPs) was assessed using quantitative real-time polymerase chain reaction in tumors and paired adjacent nonneoplastic tissues from 68 posttreatment breast carcinoma patients. Eleven candidate genes were then evaluated in an independent series of 50 pretreatment patients. Protein expression of the most significant genes was confirmed by immunoblotting. AKR1A1 was significantly overexpressed and AKR1C1-4, KCNAB1, CYP2C19, CYP3A4, and CYP3A5 downregulated in tumors compared with control nonneoplastic tissues after correction for multiple testing. Significant association of CYP2B6 transcript levels in tumors with expression of hormonal receptors was found in the posttreatment set and replicated in the pretreatment set of patients. Significantly higher intratumoral levels of AKR1C1, AKR1C2, or CYP2W1 were found in responders to neoadjuvant chemotherapy compared with nonresponders. Patients with high AKR7A3 or CYP2B6 levels in the pretreatment set had significantly longer disease-free survival than patients with low levels. Protein products of AKR1C1, AKR1C2, AKR7A3, CYP3A4, and carbonyl reductase (CBR1) were found in tumors and those of AKR1C1, AKR7A3, and CBR1 correlated with their transcript levels. Small interfering RNA-directed knockdown of AKR1C2 or vector-mediated upregulation of CYP3A4 in MDA-MB-231 model cell line had no effect on cell proliferation after paclitaxel treatment in vitro. Prognostic and predictive roles of drug-metabolizing enzymes strikingly differ between posttreatment and pretreatment breast carcinoma patients. Mechanisms of action of AKR1C2, AKR7A3, CYP2B6, CYP3A4, and CBR1 should continue to be further followed in breast carcinoma patients and models.
650    _2
$a aldehydreduktasa $x biosyntéza $x genetika $7 D000449
650    _2
$a nádory prsu $x genetika $x metabolismus $x patologie $7 D001943
650    _2
$a proliferace buněk $7 D049109
650    _2
$a systém (enzymů) cytochromů P-450 $x biosyntéza $x genetika $7 D003577
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průtoková cytometrie $7 D005434
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a imunoblotting $7 D015151
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
650    _2
$a RNA nádorová $x genetika $7 D012334
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Brynychová, Veronika $7 xx0323150
700    1_
$a Václavíková, Radka $7 xx0142918
700    1_
$a Ehrlichová, Marie $7 xx0067467
700    1_
$a Vrána, David $7 xx0103187
700    1_
$a Pecha, Václav, $d 1948- $7 xx0103675
700    1_
$a Trnková, Markéta $7 xx0158385
700    1_
$a Kodet, Roman, $d 1953- $7 nlk19990073380
700    1_
$a Mrhalová, Marcela $7 xx0062381
700    1_
$a Kubáčková, Kateřina $7 xx0083614
700    1_
$a Gatěk, Jiří, $d 1950- $7 xx0052958
700    1_
$a Vážan, Petr $7 xx0143266
700    1_
$a Souček, Pavel $7 xx0060511
773    0_
$w MED00012436 $t Medicine $x 1536-5964 $g Roč. 93, č. 28 (2014), s. e255
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25526449 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20191030131737 $b ABA008
999    __
$a ok $b bmc $g 1071538 $s 896835
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 93 $c 28 $d e255 $i 1536-5964 $m Medicine $n Medicine $x MED00012436
GRA    __
$a NT14055 $p MZ0
LZP    __
$a Pubmed-20150420

Najít záznam

Citační ukazatele

Možnosti archivace